FDA Orange Book
Generic for Tussionex Pennkinetic
Tussionex Pennkinetic contains chlorpheniramine polistirex and hydrocodone polistirex. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Tussionex Pennkinetic is chlorpheniramine polistirex and hydrocodone polistirex. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
Run it in Rivvi
Map Tussionex Pennkinetic and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Tussionex Pennkinetic products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| suspension, extended release, oral | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | Discontinued | None | 1 | None |
NDA 019111, held by UCB INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic chlorpheniramine polistirex and hydrocodone polistirex
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| TRIS PHARMA INC | 091632 | None (No TE code listed) | October 1, 2010 | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML |
Questions
Is there a generic for Tussionex Pennkinetic?
Yes. The generic name for Tussionex Pennkinetic is chlorpheniramine polistirex and hydrocodone polistirex. 1 company holds an active FDA approval (ANDA) for a generic version in the Orange Book.
What is the generic name for Tussionex Pennkinetic?
The active ingredient in Tussionex Pennkinetic is chlorpheniramine polistirex and hydrocodone polistirex, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.